Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urinary Bladder Neoplasms | 33 | 2024 | 2223 | 5.210 |
Why?
|
DNA Repair | 16 | 2024 | 2041 | 1.930 |
Why?
|
DNA Repair-Deficiency Disorders | 3 | 2024 | 37 | 1.710 |
Why?
|
Prostatic Neoplasms | 34 | 2024 | 11103 | 1.640 |
Why?
|
DNA Damage | 10 | 2023 | 2443 | 1.270 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 8 | 2023 | 106 | 1.100 |
Why?
|
Muscles | 7 | 2023 | 1567 | 1.020 |
Why?
|
Brachytherapy | 8 | 2021 | 1223 | 0.870 |
Why?
|
Cystectomy | 9 | 2024 | 634 | 0.860 |
Why?
|
Anus Neoplasms | 4 | 2024 | 329 | 0.850 |
Why?
|
Ataxia Telangiectasia | 1 | 2023 | 107 | 0.840 |
Why?
|
Urinary Bladder | 5 | 2023 | 1152 | 0.810 |
Why?
|
Carcinoma, Transitional Cell | 5 | 2024 | 782 | 0.750 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2021 | 205 | 0.740 |
Why?
|
DNA Nucleotidyltransferases | 4 | 2010 | 175 | 0.740 |
Why?
|
Neoplasm Invasiveness | 15 | 2024 | 3591 | 0.740 |
Why?
|
Prostatectomy | 9 | 2024 | 1825 | 0.720 |
Why?
|
Camptothecin | 1 | 2024 | 591 | 0.700 |
Why?
|
Radiosurgery | 3 | 2024 | 1339 | 0.650 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 636 | 0.630 |
Why?
|
Antineoplastic Agents | 11 | 2023 | 13630 | 0.600 |
Why?
|
Cisplatin | 10 | 2023 | 1651 | 0.600 |
Why?
|
Mastectomy, Segmental | 2 | 2013 | 955 | 0.580 |
Why?
|
Gene Amplification | 1 | 2021 | 1084 | 0.560 |
Why?
|
Allergy and Immunology | 1 | 2018 | 177 | 0.560 |
Why?
|
Recombination, Genetic | 3 | 2010 | 1518 | 0.490 |
Why?
|
Androgen Antagonists | 8 | 2024 | 1408 | 0.480 |
Why?
|
Retinoblastoma | 2 | 2014 | 319 | 0.480 |
Why?
|
Radiation Oncology | 3 | 2018 | 563 | 0.470 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2021 | 801 | 0.470 |
Why?
|
Neoplasms, Second Primary | 4 | 2023 | 1051 | 0.410 |
Why?
|
Bacterial Proteins | 5 | 2010 | 3838 | 0.410 |
Why?
|
Retinal Neoplasms | 1 | 2014 | 148 | 0.410 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 899 | 0.400 |
Why?
|
Genomics | 7 | 2023 | 5828 | 0.400 |
Why?
|
Mutation | 20 | 2024 | 30006 | 0.380 |
Why?
|
Prostate | 8 | 2024 | 1772 | 0.380 |
Why?
|
Fanconi Anemia | 1 | 2014 | 324 | 0.380 |
Why?
|
Sesquiterpenes | 2 | 2023 | 176 | 0.380 |
Why?
|
Neoplasm Staging | 13 | 2024 | 11118 | 0.370 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2021 | 3591 | 0.370 |
Why?
|
Humans | 103 | 2024 | 761098 | 0.360 |
Why?
|
DNA | 6 | 2024 | 7189 | 0.350 |
Why?
|
Salvage Therapy | 1 | 2016 | 1264 | 0.340 |
Why?
|
Urologic Neoplasms | 3 | 2019 | 314 | 0.340 |
Why?
|
Prostate-Specific Antigen | 7 | 2022 | 2465 | 0.330 |
Why?
|
Deglutition | 1 | 2010 | 208 | 0.330 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2024 | 4021 | 0.320 |
Why?
|
Mutation, Missense | 1 | 2018 | 2567 | 0.320 |
Why?
|
Neoplasms | 7 | 2024 | 22125 | 0.310 |
Why?
|
Immunotherapy | 6 | 2024 | 4642 | 0.310 |
Why?
|
Laryngeal Neoplasms | 1 | 2012 | 514 | 0.310 |
Why?
|
BRCA2 Protein | 5 | 2023 | 797 | 0.310 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 11732 | 0.300 |
Why?
|
Poly(ADP-ribose) Polymerases | 2 | 2023 | 426 | 0.300 |
Why?
|
Germ-Line Mutation | 4 | 2022 | 1852 | 0.290 |
Why?
|
Models, Molecular | 6 | 2014 | 5413 | 0.290 |
Why?
|
Computational Biology | 2 | 2019 | 3499 | 0.290 |
Why?
|
Genes, BRCA2 | 4 | 2023 | 591 | 0.280 |
Why?
|
Education, Medical | 1 | 2018 | 1725 | 0.280 |
Why?
|
Watchful Waiting | 3 | 2019 | 489 | 0.270 |
Why?
|
Cell Cycle Proteins | 1 | 2018 | 3443 | 0.270 |
Why?
|
Disease-Free Survival | 8 | 2024 | 6817 | 0.270 |
Why?
|
Male | 60 | 2024 | 360675 | 0.260 |
Why?
|
Patient Preference | 1 | 2013 | 926 | 0.260 |
Why?
|
Cell Cycle | 1 | 2014 | 2926 | 0.260 |
Why?
|
Speech | 1 | 2010 | 554 | 0.250 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2018 | 1784 | 0.250 |
Why?
|
Protein Multimerization | 1 | 2010 | 974 | 0.250 |
Why?
|
Breast Neoplasms | 4 | 2019 | 20981 | 0.240 |
Why?
|
DNA Mismatch Repair | 2 | 2018 | 428 | 0.240 |
Why?
|
Borrelia burgdorferi | 1 | 2007 | 183 | 0.240 |
Why?
|
BRCA1 Protein | 4 | 2023 | 1149 | 0.240 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2021 | 549 | 0.220 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2023 | 5300 | 0.210 |
Why?
|
Aged | 39 | 2024 | 169266 | 0.210 |
Why?
|
Biomedical Research | 1 | 2018 | 3429 | 0.210 |
Why?
|
Cell Line, Tumor | 6 | 2024 | 16947 | 0.210 |
Why?
|
Lung Neoplasms | 3 | 2024 | 13382 | 0.210 |
Why?
|
Seminoma | 1 | 2023 | 134 | 0.200 |
Why?
|
Combined Modality Therapy | 6 | 2024 | 8519 | 0.200 |
Why?
|
DNA, Bacterial | 1 | 2007 | 1470 | 0.190 |
Why?
|
Tumor Microenvironment | 3 | 2023 | 3869 | 0.190 |
Why?
|
Recombinases | 2 | 2013 | 67 | 0.190 |
Why?
|
Radiotherapy | 2 | 2019 | 1498 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2023 | 9278 | 0.190 |
Why?
|
Organs at Risk | 2 | 2014 | 359 | 0.190 |
Why?
|
Tumor Burden | 2 | 2024 | 1892 | 0.190 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2013 | 880 | 0.190 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2021 | 696 | 0.180 |
Why?
|
DNA-Binding Proteins | 3 | 2020 | 9566 | 0.180 |
Why?
|
Retrospective Studies | 25 | 2024 | 80673 | 0.180 |
Why?
|
Prognosis | 15 | 2024 | 29672 | 0.180 |
Why?
|
Radiotherapy Dosage | 4 | 2019 | 2898 | 0.180 |
Why?
|
Papillomavirus Infections | 2 | 2024 | 1615 | 0.180 |
Why?
|
Survival Analysis | 6 | 2020 | 10083 | 0.170 |
Why?
|
Ki-67 Antigen | 1 | 2021 | 627 | 0.160 |
Why?
|
Genes, Neoplasm | 2 | 2017 | 370 | 0.160 |
Why?
|
Neoplasm Proteins | 3 | 2020 | 3594 | 0.160 |
Why?
|
Ultraviolet Rays | 2 | 2023 | 1079 | 0.160 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 491 | 0.150 |
Why?
|
Middle Aged | 33 | 2024 | 220835 | 0.150 |
Why?
|
GTP Phosphohydrolases | 1 | 2021 | 517 | 0.150 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 218 | 0.150 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 116 | 0.150 |
Why?
|
DNA Polymerase III | 1 | 2018 | 51 | 0.150 |
Why?
|
Treatment Outcome | 14 | 2023 | 64670 | 0.150 |
Why?
|
Serine | 2 | 2013 | 826 | 0.150 |
Why?
|
Aged, 80 and over | 16 | 2024 | 58946 | 0.150 |
Why?
|
Microsatellite Instability | 2 | 2018 | 716 | 0.150 |
Why?
|
DNA Polymerase II | 1 | 2018 | 104 | 0.150 |
Why?
|
Signal Transduction | 3 | 2023 | 23415 | 0.140 |
Why?
|
DNA Copy Number Variations | 3 | 2021 | 2024 | 0.140 |
Why?
|
Carcinoma | 2 | 2019 | 2328 | 0.140 |
Why?
|
Female | 32 | 2024 | 392458 | 0.140 |
Why?
|
Testicular Neoplasms | 1 | 2023 | 800 | 0.140 |
Why?
|
DNA Breaks, Double-Stranded | 2 | 2019 | 612 | 0.140 |
Why?
|
Kallikreins | 1 | 2018 | 220 | 0.140 |
Why?
|
INDEL Mutation | 1 | 2017 | 265 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2024 | 963 | 0.130 |
Why?
|
Head and Neck Neoplasms | 1 | 2010 | 2896 | 0.130 |
Why?
|
Travel | 2 | 2021 | 796 | 0.130 |
Why?
|
DNA Mutational Analysis | 3 | 2018 | 4109 | 0.130 |
Why?
|
Dimerization | 2 | 2008 | 888 | 0.130 |
Why?
|
Neoadjuvant Therapy | 6 | 2024 | 2827 | 0.120 |
Why?
|
Microsatellite Repeats | 1 | 2017 | 782 | 0.120 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 339 | 0.120 |
Why?
|
Microtubule-Associated Proteins | 1 | 2020 | 1074 | 0.120 |
Why?
|
Neuropeptides | 1 | 2020 | 944 | 0.120 |
Why?
|
Follow-Up Studies | 8 | 2021 | 39121 | 0.120 |
Why?
|
Databases, Factual | 6 | 2019 | 7969 | 0.120 |
Why?
|
Immunohistochemistry | 4 | 2024 | 11066 | 0.120 |
Why?
|
Radiation Tolerance | 1 | 2016 | 478 | 0.120 |
Why?
|
Protein Conformation | 4 | 2014 | 3936 | 0.110 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 1822 | 0.110 |
Why?
|
Neuroendocrine Tumors | 1 | 2020 | 641 | 0.110 |
Why?
|
Quality of Life | 2 | 2013 | 13362 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2018 | 610 | 0.110 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 1745 | 0.110 |
Why?
|
Prospective Studies | 11 | 2024 | 54419 | 0.110 |
Why?
|
Colon, Sigmoid | 1 | 2014 | 124 | 0.110 |
Why?
|
DNA Cleavage | 1 | 2013 | 56 | 0.110 |
Why?
|
Stromal Cells | 1 | 2019 | 1329 | 0.110 |
Why?
|
SEER Program | 4 | 2019 | 1450 | 0.110 |
Why?
|
Mice, SCID | 1 | 2018 | 2621 | 0.110 |
Why?
|
Biocatalysis | 1 | 2013 | 168 | 0.110 |
Why?
|
Acids | 1 | 2013 | 124 | 0.110 |
Why?
|
Genomic Instability | 1 | 2017 | 709 | 0.110 |
Why?
|
Carboplatin | 2 | 2015 | 793 | 0.100 |
Why?
|
Crystallography, X-Ray | 2 | 2008 | 1982 | 0.100 |
Why?
|
Cohort Studies | 10 | 2024 | 41486 | 0.100 |
Why?
|
Mutant Proteins | 2 | 2013 | 489 | 0.100 |
Why?
|
Protein Structure, Quaternary | 2 | 2010 | 427 | 0.100 |
Why?
|
Urothelium | 1 | 2014 | 269 | 0.100 |
Why?
|
Adenocarcinoma | 2 | 2020 | 6340 | 0.100 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2018 | 3634 | 0.100 |
Why?
|
Genome | 1 | 2020 | 1737 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2013 | 10213 | 0.100 |
Why?
|
Cell Division | 1 | 2018 | 4451 | 0.090 |
Why?
|
Evaluation Studies as Topic | 1 | 2013 | 1624 | 0.090 |
Why?
|
Hydroxyurea | 1 | 2012 | 284 | 0.090 |
Why?
|
Protein Kinases | 1 | 2018 | 1607 | 0.090 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2015 | 487 | 0.090 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2014 | 592 | 0.090 |
Why?
|
Ultracentrifugation | 1 | 2010 | 182 | 0.090 |
Why?
|
Insulin Resistance | 1 | 2024 | 3951 | 0.090 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2577 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2024 | 8529 | 0.090 |
Why?
|
Arginine | 1 | 2013 | 921 | 0.080 |
Why?
|
Radiotherapy, Conformal | 1 | 2013 | 548 | 0.080 |
Why?
|
Gene Expression Profiling | 3 | 2020 | 9416 | 0.080 |
Why?
|
Rectum | 1 | 2014 | 891 | 0.080 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2017 | 1520 | 0.080 |
Why?
|
Genital Neoplasms, Female | 1 | 2014 | 532 | 0.080 |
Why?
|
Binding Sites | 2 | 2008 | 5993 | 0.080 |
Why?
|
Carcinoma, Renal Cell | 1 | 2023 | 3163 | 0.080 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2012 | 646 | 0.080 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2012 | 620 | 0.080 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1882 | 0.080 |
Why?
|
Promoter Regions, Genetic | 1 | 2019 | 5775 | 0.070 |
Why?
|
DNA Methylation | 2 | 2019 | 4386 | 0.070 |
Why?
|
Animals | 6 | 2024 | 168083 | 0.070 |
Why?
|
Radiometry | 1 | 2013 | 812 | 0.070 |
Why?
|
Substrate Specificity | 2 | 2013 | 1768 | 0.070 |
Why?
|
Cell Line | 2 | 2018 | 15542 | 0.070 |
Why?
|
Oligonucleotides | 1 | 2010 | 563 | 0.070 |
Why?
|
Mice | 3 | 2024 | 81324 | 0.070 |
Why?
|
Germ Cells | 2 | 2022 | 632 | 0.070 |
Why?
|
Nucleic Acid Conformation | 2 | 2010 | 896 | 0.070 |
Why?
|
Fluorouracil | 1 | 2012 | 1642 | 0.070 |
Why?
|
Crystallization | 1 | 2008 | 528 | 0.070 |
Why?
|
Genome, Human | 2 | 2018 | 4423 | 0.070 |
Why?
|
Risk Assessment | 6 | 2020 | 24013 | 0.070 |
Why?
|
Kidney Neoplasms | 1 | 2023 | 4251 | 0.070 |
Why?
|
Catalysis | 1 | 2008 | 763 | 0.070 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 1089 | 0.060 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2019 | 3512 | 0.060 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 1655 | 0.060 |
Why?
|
Bone Neoplasms | 1 | 2017 | 2527 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 5662 | 0.060 |
Why?
|
Survival Rate | 4 | 2020 | 12727 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2021 | 7844 | 0.060 |
Why?
|
Visual Acuity | 1 | 2014 | 2677 | 0.060 |
Why?
|
Paclitaxel | 1 | 2012 | 1730 | 0.060 |
Why?
|
Logistic Models | 4 | 2020 | 13254 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5318 | 0.060 |
Why?
|
Radiography | 1 | 2014 | 6975 | 0.050 |
Why?
|
Androgens | 2 | 2021 | 1283 | 0.050 |
Why?
|
DNA Replication | 2 | 2022 | 1415 | 0.050 |
Why?
|
Mice, Knockout | 1 | 2018 | 14393 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3094 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3216 | 0.050 |
Why?
|
Palliative Care | 1 | 2017 | 3593 | 0.050 |
Why?
|
Sequence Alignment | 1 | 2007 | 2175 | 0.050 |
Why?
|
Time Factors | 3 | 2018 | 39953 | 0.050 |
Why?
|
Adult | 10 | 2021 | 221083 | 0.050 |
Why?
|
Ribonuclease H | 1 | 2022 | 50 | 0.050 |
Why?
|
Propensity Score | 2 | 2021 | 1913 | 0.050 |
Why?
|
Genome, Bacterial | 1 | 2007 | 785 | 0.050 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2022 | 101 | 0.050 |
Why?
|
Orchiectomy | 1 | 2023 | 463 | 0.050 |
Why?
|
Multivariate Analysis | 3 | 2020 | 12058 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6919 | 0.050 |
Why?
|
Staphylococcus aureus | 1 | 2009 | 1450 | 0.050 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 3689 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5427 | 0.050 |
Why?
|
Proportional Hazards Models | 3 | 2020 | 12467 | 0.040 |
Why?
|
BCG Vaccine | 1 | 2023 | 369 | 0.040 |
Why?
|
Age Factors | 2 | 2017 | 18385 | 0.040 |
Why?
|
Cyclin E | 1 | 2020 | 155 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2020 | 2914 | 0.040 |
Why?
|
Protein Structure, Tertiary | 1 | 2007 | 3779 | 0.040 |
Why?
|
Urethra | 1 | 2021 | 405 | 0.040 |
Why?
|
Catalytic Domain | 2 | 2013 | 702 | 0.040 |
Why?
|
Deoxycytidine | 1 | 2023 | 878 | 0.040 |
Why?
|
Geography | 1 | 2021 | 652 | 0.040 |
Why?
|
Disease Management | 2 | 2019 | 2508 | 0.040 |
Why?
|
Ovarian Neoplasms | 1 | 2015 | 4853 | 0.040 |
Why?
|
Risk Factors | 5 | 2019 | 74219 | 0.040 |
Why?
|
Time-Lapse Imaging | 1 | 2018 | 194 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 4 | 2022 | 17889 | 0.040 |
Why?
|
Pelvis | 1 | 2022 | 734 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2019 | 781 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6482 | 0.040 |
Why?
|
Drug Synergism | 1 | 2021 | 1756 | 0.040 |
Why?
|
Allelic Imbalance | 1 | 2017 | 77 | 0.040 |
Why?
|
Probability | 1 | 2022 | 2478 | 0.030 |
Why?
|
Oncogene Proteins | 1 | 2020 | 717 | 0.030 |
Why?
|
Anal Canal | 1 | 2019 | 374 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2019 | 4908 | 0.030 |
Why?
|
Gene Dosage | 1 | 2020 | 1217 | 0.030 |
Why?
|
Tumor Escape | 1 | 2019 | 371 | 0.030 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2020 | 423 | 0.030 |
Why?
|
Infant | 2 | 2014 | 36164 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2021 | 15513 | 0.030 |
Why?
|
Amino Acid Sequence | 1 | 2007 | 13404 | 0.030 |
Why?
|
Body Composition | 1 | 2024 | 2427 | 0.030 |
Why?
|
Child, Preschool | 2 | 2014 | 42217 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2927 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2020 | 2855 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1702 | 0.030 |
Why?
|
Molecular Sequence Data | 1 | 2007 | 17598 | 0.030 |
Why?
|
Genes, BRCA1 | 1 | 2017 | 754 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2021 | 1966 | 0.030 |
Why?
|
Genetic Markers | 1 | 2019 | 2599 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2019 | 1348 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2022 | 1891 | 0.030 |
Why?
|
Biopsy | 1 | 2024 | 6781 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2018 | 15308 | 0.020 |
Why?
|
Molecular Imaging | 1 | 2018 | 819 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2018 | 1741 | 0.020 |
Why?
|
Conserved Sequence | 1 | 2014 | 1162 | 0.020 |
Why?
|
Gene Silencing | 1 | 2017 | 1496 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 20600 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2019 | 3155 | 0.020 |
Why?
|
Incidence | 2 | 2022 | 21357 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5869 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2017 | 1409 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2020 | 2638 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2024 | 4947 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2013 | 2478 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2017 | 1744 | 0.020 |
Why?
|
Endometrial Neoplasms | 1 | 2018 | 1365 | 0.020 |
Why?
|
RNA-Binding Proteins | 1 | 2017 | 1855 | 0.020 |
Why?
|
Liver | 1 | 2024 | 7513 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2019 | 5478 | 0.020 |
Why?
|
Observer Variation | 1 | 2014 | 2611 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2896 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2018 | 2452 | 0.020 |
Why?
|
Cause of Death | 1 | 2018 | 3688 | 0.020 |
Why?
|
Risk | 1 | 2019 | 9614 | 0.020 |
Why?
|
Decision Making | 1 | 2021 | 3925 | 0.020 |
Why?
|
Neutrophils | 1 | 2019 | 3763 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 3197 | 0.020 |
Why?
|
Odds Ratio | 1 | 2019 | 9648 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2021 | 10421 | 0.020 |
Why?
|
Kinetics | 1 | 2013 | 6312 | 0.020 |
Why?
|
United States | 3 | 2018 | 72337 | 0.020 |
Why?
|
Mutagenesis | 1 | 2009 | 1227 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2015 | 3700 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2010 | 3577 | 0.010 |
Why?
|
Genotype | 1 | 2018 | 12983 | 0.010 |
Why?
|
Prevalence | 1 | 2019 | 15717 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2017 | 12743 | 0.010 |
Why?
|
Lung | 1 | 2021 | 9979 | 0.010 |
Why?
|
Phosphorylation | 1 | 2013 | 8303 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2021 | 18217 | 0.010 |
Why?
|
Disease Progression | 1 | 2018 | 13506 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2019 | 10203 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2019 | 20120 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8663 | 0.010 |
Why?
|
Phenotype | 1 | 2018 | 16572 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 15915 | 0.010 |
Why?
|
Models, Biological | 1 | 2010 | 9455 | 0.010 |
Why?
|
Young Adult | 1 | 2013 | 59199 | 0.000 |
Why?
|
Child | 1 | 2013 | 80134 | 0.000 |
Why?
|
Adolescent | 1 | 2013 | 88271 | 0.000 |
Why?
|